Aftate, Pitrex , Tinactin
Classifications: antiinfective; antifungal antibiotic
Pregnancy Category: C


1% cream, solution, gel, powder, spray


Synthetic topical antifungal agent. Action mechanism not clear, but has been shown that tolnaftate distorts hyphae and stunts mycelial growth on susceptible fungi.

Therapeutic Effects

Fungistatic or fungicidal to Microsporum, specifically M. gypseum, M. canis, M. audouinii, M. japonicum, Trichophyton, T. rubrum, T. schoenleinii, T. tonsurans, and Epidermophyton floccosum, but ineffective against Candida albicans, Cryptococcus neoformans, Aspergillus fumigatus, bacteria, protozoa, and viruses.


Tinea pedis (athlete's foot), tinea cruris (jock itch), tinea corporis (body ringworm); also tinea capitis and tinea unguium if infection is superficial, plantar or palmar lesions adjunctively with keratolytic agents, and tinea versicolor (caused by Malassezia furfur).


Skin irritations prior to therapy, nail and scalp infections. Safety during pregnancy (category C), lactation, or by children <2 y is not established.

Cautious Use

Excoriated skin.

Route & Dosage

Tinea Infestations
Adult/Child: Topical Apply 0.5–1 cm (1/4– in) of cream or 3 drops of solution b.i.d. in morning and evening; powder may be used prophylactically in normally moist areas



Adverse Effects (1%)

Skin: Local irritation, stinging of skin from aerosol formulation.


Drug: No clinically significant interactions established.


Not studied.

Nursing Implications

Patient & Family Education

Common adverse effects in italic, life-threatening effects underlined; generic names in bold; classifications in SMALL CAPS; Canadian drug name; Prototype drug